User profiles for Peter W Horby

Peter W. Horby

Professor of Emerging Infectious Diseases, University of Oxford
Verified email at ndm.ox.ac.uk
Cited by 73209

[PDF][PDF] SARS-CoV-2 Omicron-B. 1.1. 529 leads to widespread escape from neutralizing antibody responses

…, EM Harrison, JA Hiscox, AYW Ho, PW Horby… - Cell, 2022 - cell.com
On 24 th November 2021, the sequence of a new SARS-CoV-2 viral isolate Omicron-B.1.1.529
was announced, containing far more mutations in Spike (S) than previously reported …

Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study

…, L Sigfrid, S Halpin, C Jackson, C Gamble, PW Horby… - bmj, 2020 - bmj.com
Objective To characterise the clinical features of patients admitted to hospital with coronavirus
disease 2019 (covid-19) in the United Kingdom during the growth phase of the first wave …

[HTML][HTML] A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19

…, C Huang, T Jaki, FG Hayden, PW Horby… - New England journal …, 2020 - Mass Medical Soc
Background No therapeutics have yet been proven effective for the treatment of severe
illness caused by SARS-CoV-2. Methods We conducted a randomized, controlled, open-label …

[HTML][HTML] A novel coronavirus outbreak of global health concern

C Wang, PW Horby, FG Hayden, GF Gao - The lancet, 2020 - thelancet.com
However, this information was from what now appears to be first-generation cases from a point
source, but at the time it seems that a second generation, and perhaps a third generation, …

[HTML][HTML] Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

…, Y Wan, H Qin, Y Jiang, T Jaki, FG Hayden, PW Horby… - The lancet, 2020 - thelancet.com
Background No specific antiviral drug has been proven effective for treatment of patients
with severe coronavirus disease 2019 (COVID-19). Remdesivir (GS-5734), a nucleoside …

Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C …

…, S Halpin, HE Hardwick, KA Holden, PW Horby… - bmj, 2020 - bmj.com
Objective To develop and validate a pragmatic risk score to predict mortality in patients admitted
to hospital with coronavirus disease 2019 (covid-19). Design Prospective observational …

[HTML][HTML] Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

PW Horby, M Mafham, JL Bell, L Linsell, N Staplin… - The Lancet, 2020 - thelancet.com
Background Lopinavir–ritonavir has been proposed as a treatment for COVID-19 on the basis
of in vitro activity, preclinical studies, and observational studies. Here, we report the results …

Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study

…, IP Sinha, PL Olliaro, JS Nguyen-Van-Tam, PW Horby… - bmj, 2020 - bmj.com
Objective To characterise the clinical features of children and young people admitted to
hospital with laboratory confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-…

[HTML][HTML] Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP …

…, CA Green, JA Hiscox, AYW Ho, PW Horby… - The Lancet …, 2021 - thelancet.com
Background Microbiological characterisation of co-infections and secondary infections in
patients with COVID-19 is lacking, and antimicrobial use is high. We aimed to describe …

[HTML][HTML] Evaluation of convalescent plasma for Ebola virus disease in Guinea

…, P Gallian, S Baize, PW Horby… - … England Journal of …, 2016 - Mass Medical Soc
Background In the wake of the recent outbreak of Ebola virus disease (EVD) in several
African countries, the World Health Organization prioritized the evaluation of treatment with …